Apimeds Pharmaceuticals US APUS
NYSE APUS
$3.20 -0.21 (-6.14%)
As of: Oct 21, 2026 · 3:59 PM EDT

Apimeds Pharmaceuticals US (APUS) Accumulated Expenses (2025 - 2026)

Updated

Apimeds Pharmaceuticals US (APUS) posted Accumulated Expenses of $780,000 for Q2 2026.

Analysis

Apimeds Pharmaceuticals US (APUS) Accumulated Expenses (2025 - 2026) Analysis & Trends

At the end of FY2025, Apimeds Pharmaceuticals US's Accumulated Expenses came in at $500,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Apimeds Pharmaceuticals US 5.44 Mn -14.20 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 780,000.00
Dec 31, 2025 500,000.00
API Access

Apimeds Pharmaceuticals US Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=APUS&period=max&api_key=YOUR_API_KEY